IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of inducement stock options to a new employee on March 27, 2025. The Compensation Committee approved non-qualified stock options to purchase 17,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $17.43 per share, matching the closing price of IDEAYA's stock on the Nasdaq Global Select Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years, contingent on continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato il conferimento di opzioni su azioni di incentivazione a un nuovo dipendente il 27 marzo 2025. Il Comitato Compensi ha approvato opzioni su azioni non qualificate per l'acquisto di 17.600 azioni ordinarie nell'ambito del Piano di Incentivazione per l'Occupazione 2023 dell'azienda.
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $17.43 per azione, corrispondente al prezzo di chiusura delle azioni di IDEAYA sul Nasdaq Global Select Market alla data di concessione. Queste opzioni hanno un termine di 10 anni e si matureranno nel corso di quattro anni, con il 25% che matura dopo il primo anno e il rimanente 75% che matura in rate mensili nei tre anni successivi, a condizione di un'occupazione continuativa.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado la concesión de opciones sobre acciones de incentivo a un nuevo empleado el 27 de marzo de 2025. El Comité de Compensación aprobó opciones sobre acciones no calificadas para adquirir 17,600 acciones ordinarias bajo el Plan de Incentivo de Empleo 2023 de la compañía.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $17.43 por acción, igualando el precio de cierre de las acciones de IDEAYA en el Nasdaq Global Select Market en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con el 25% consolidándose después del primer año y el 75% restante consolidándose en cuotas mensuales durante los tres años siguientes, sujeto a la continuación del empleo.
IDEAYA Biosciences (NASDAQ: IDYA)는 2025년 3월 27일에 새로운 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 회사의 2023 고용 유인 인센티브 수여 계획에 따라 17,600주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
주식 옵션은 부여일의 Nasdaq Global Select Market에서 IDEAYA의 주식 종가와 일치하는 $17.43의 행사 가격으로 부여되었습니다. 이 옵션은 10년의 기간을 가지며, 4년에 걸쳐 분할되어 1년 후에 25%가 확정되고, 나머지 75%는 다음 3년에 걸쳐 월별 할부로 확정되며, 지속적인 고용에 따라 달라집니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé l'octroi d'options d'achat d'actions d'incitation à un nouvel employé le 27 mars 2025. Le Comité de Rémunération a approuvé des options d'achat d'actions non qualifiées pour l'acquisition de 17 600 actions ordinaires dans le cadre du Plan d'Incentive à l'Emploi 2023 de l'entreprise.
Les options d'achat d'actions ont été accordées à un prix d'exercice de $17.43 par action, correspondant au prix de clôture des actions d'IDEAYA sur le Nasdaq Global Select Market à la date d'octroi. Ces options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et les 75 % restants acquises en versements mensuels au cours des trois années suivantes, sous réserve d'un emploi continu.
IDEAYA Biosciences (NASDAQ: IDYA) hat die Gewährung von Anreiz-Aktienoptionen an einen neuen Mitarbeiter am 27. März 2025 bekannt gegeben. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 17.600 Stammaktien im Rahmen des Unternehmensplans für Anreizvergütungen 2023.
Die Aktienoptionen wurden zu einem Ausübungspreis von $17.43 pro Aktie gewährt, was dem Schlusskurs der IDEAYA-Aktien am Nasdaq Global Select Market am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre hinweg fällig, wobei 25 % nach dem ersten Jahr und die verbleibenden 75 % in monatlichen Raten über die folgenden drei Jahre fällig werden, abhängig von einer fortgesetzten Beschäftigung.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302413947.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the exercise price for IDYA's newly granted stock options in March 2025?
How many shares are covered by IDYA's March 2025 inducement stock options grant?
What is the vesting schedule for IDYA's March 2025 inducement stock options?
How long is the term of IDYA's March 2025 inducement stock options?
